ImmunoPrecise Antibodies Advances Therapeutic Innovation With Rabbit Antibody Developments, Says Rabbit B Cell Select Drives Clinical Breakthroughs In Cancer Treatment
ImmunoPrecise Antibodies Advances Therapeutic Innovation With Rabbit Antibody Developments, Says Rabbit B Cell Select Drives Clinical Breakthroughs In Cancer Treatment
Rabbit B Cell Select Drives Clinical Breakthroughs in Cancer Treatment
兔b细胞选择驱动癌症治疗的临床突破
ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using IPA's proprietary B Cell Select platform for the clinical-stage company, OncoResponse Inc. This achievement underscores IPA's leadership as a Contract Research Organization creating high-quality therapeutic antibodies, while pioneering work in the field of rabbit monoclonal antibody development. These antibodies are rapidly gaining recognition as a unique tool in therapies due to their distinctive properties, advancing into clinical trials aimed at improving patient outcomes.
ImmunoPrecise Antibodies Ltd.（以下简称"IPA"）（纳斯达克：IPA）是一家人工智能驱动的生物治疗研究和技术公司，今天自豪地宣布通过使用IPA专有的b细胞选择平台设计和开发的兔单克隆抗体在临床阶段公司OncoResponse Inc.取得的临床进展。这一成就彰显了IPA作为一家合同研究组织在创建高质量治疗性抗体方面的领导地位，同时开拓了兔单克隆抗体开发领域的工作。由于其独特的特性，这些抗体正在迅速获得认可作为治疗中的独特工具，并正在进入旨在改善患者预后的临床试验。
